PL2392326T3 - Składnik sylibininowy do leczenia zapalenia wątroby - Google Patents

Składnik sylibininowy do leczenia zapalenia wątroby

Info

Publication number
PL2392326T3
PL2392326T3 PL11005445T PL11005445T PL2392326T3 PL 2392326 T3 PL2392326 T3 PL 2392326T3 PL 11005445 T PL11005445 T PL 11005445T PL 11005445 T PL11005445 T PL 11005445T PL 2392326 T3 PL2392326 T3 PL 2392326T3
Authority
PL
Poland
Prior art keywords
hepatitis
treatment
silibinin component
silibinin
component
Prior art date
Application number
PL11005445T
Other languages
English (en)
Inventor
Peter Ferenci
Ulrich Mengs
Ralf-Torsten Pohl
Lucio Claudio Rovati
Massimo Maria D'amato
Original Assignee
Madaus Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madaus Gmbh filed Critical Madaus Gmbh
Publication of PL2392326T3 publication Critical patent/PL2392326T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11005445T 2007-11-15 2008-11-14 Składnik sylibininowy do leczenia zapalenia wątroby PL2392326T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98816807P 2007-11-15 2007-11-15
EP07022187 2007-11-15
EP08005459 2008-03-25
EP11005445.9A EP2392326B9 (en) 2007-11-15 2008-11-14 Silibinin component for the treatment of hepatitis
EP08849759A EP2219642B1 (en) 2007-11-15 2008-11-14 Silibinin component for the treatment of hepatitis

Publications (1)

Publication Number Publication Date
PL2392326T3 true PL2392326T3 (pl) 2018-07-31

Family

ID=40259958

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08849759T PL2219642T3 (pl) 2007-11-15 2008-11-14 Komponent sylibininy do leczenia zapalenia wątroby
PL11005445T PL2392326T3 (pl) 2007-11-15 2008-11-14 Składnik sylibininowy do leczenia zapalenia wątroby

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08849759T PL2219642T3 (pl) 2007-11-15 2008-11-14 Komponent sylibininy do leczenia zapalenia wątroby

Country Status (15)

Country Link
US (2) US20110182858A1 (pl)
EP (2) EP2219642B1 (pl)
JP (1) JP5349486B2 (pl)
KR (1) KR101435242B1 (pl)
CN (1) CN102300570B (pl)
AT (1) ATE525070T1 (pl)
AU (1) AU2008323156B2 (pl)
CA (1) CA2703834C (pl)
DK (1) DK2219642T3 (pl)
ES (2) ES2662700T3 (pl)
HK (1) HK1142270A1 (pl)
MX (1) MX2010005107A (pl)
PL (2) PL2219642T3 (pl)
PT (1) PT2219642E (pl)
WO (1) WO2009062737A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593858T3 (es) * 2009-05-14 2016-12-13 Madaus Gmbh Método para preparar silibinina amorfa
WO2011051742A1 (en) * 2009-10-28 2011-05-05 Modutech S.A. Preparation comprising amino acids and plants and its activity in the alcohol detoxification
ES2527510T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012003457T5 (de) 2011-10-21 2015-03-12 Abbvie Inc. Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20160324795A1 (en) * 2014-01-27 2016-11-10 Kaohsiung Medical University Silibinin nanoparticle and a method of treating hepatitis c thereof
AU2015222678B2 (en) * 2014-02-26 2018-11-22 Commonwealth Scientific And Industrial Research Organisation Process of forming a photoactive layer of a perovskite photoactive device
CN112022807A (zh) * 2014-10-09 2020-12-04 西西里微纳米系统技术区有限责任合作公司 用于治疗眼部疾病的用于递送水飞蓟宾和其他活性成分的纳米结构化制剂
WO2017059447A1 (en) * 2015-10-02 2017-04-06 PACHECO, Theresa Topical silibinin formulations and uses thereofor
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN111841501A (zh) * 2020-06-23 2020-10-30 五邑大学 一种治疗炎症性疾病的药物组合物及其应用
KR20230019398A (ko) * 2021-07-30 2023-02-08 경희대학교 산학협력단 항바이러스 조성물 및 이의 이용
CN117269374B (zh) * 2023-11-22 2024-01-16 汤臣倍健股份有限公司 一种水飞蓟提取物中人为掺假的鉴别方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061765A (en) * 1973-01-19 1977-12-06 Dr. Madaus & Co. Polyhydroxyphenylchromanone salts and therapeutic composition
DE3442639A1 (de) * 1984-11-22 1986-05-22 Dr. Madaus & Co, 5000 Köln Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten
DE3537656A1 (de) 1984-11-22 1986-05-22 Dr. Madaus GmbH & Co, 5000 Köln Verfahren zur herstellung von isosilybinfreiem silibinin und arzneimittel, enthaltend silibinin
IT1215291B (it) * 1985-07-17 1990-01-31 Inverni Della Beffa Spa Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche.
IT1241673B (it) 1989-10-09 1994-01-27 Istituto Biochimico Italiano Complessi di inclusione di silibinina con ciclodestrina, loro preparazione e composizioni farmaceutiche che li contengono.
DE4401902C2 (de) * 1994-01-24 2000-02-03 Madaus Ag Verwendung von Flavolignanen als Adjuvans in der Tumortherapie
JP2002504514A (ja) * 1998-02-27 2002-02-12 ニュートラマックス ラボラトリーズ，インコーポレイテッド 肝臓傷害の予防、治療及び修復のためのｌ−エルゴチオネイン、ノゲシ及びｓ−アデノシルメテオニン
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
BR9915644A (pt) * 1998-11-24 2001-08-07 Hollis Eden Pharmaceuticals Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus
US6849254B1 (en) * 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
WO2002067853A2 (en) * 2000-10-06 2002-09-06 Probiochem, Llc A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
US6699900B2 (en) 2001-04-07 2004-03-02 Jan E. Zielinski Hydrophilic and lipophilic silibinin pro-forms
CN100451501C (zh) 2003-08-26 2009-01-14 株式会社东芝 冰箱
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
CN1762345A (zh) 2005-09-29 2006-04-26 丛晓东 一种水飞蓟宾注射剂及其制备方法
CN100389767C (zh) * 2005-09-30 2008-05-28 天津药物研究院 一种含活性成分水飞蓟宾及其盐经注射给药的稳定的药物组合物
CN100534992C (zh) * 2005-12-26 2009-09-02 浙江海正药业股份有限公司 水飞蓟宾酯类衍生物及其制备方法和制备药物的用途
CN101244059B (zh) 2008-03-31 2010-11-17 广州佳科生物科技有限公司 一种复方水飞蓟宾注射剂及其制备方法和应用
CN101439018A (zh) 2008-11-11 2009-05-27 扬子江药业集团四川海蓉药业有限公司 一种静脉注射用水飞蓟宾类化合物乳剂及其制备方法

Also Published As

Publication number Publication date
CN102300570A (zh) 2011-12-28
WO2009062737A1 (en) 2009-05-22
KR20100094981A (ko) 2010-08-27
DK2219642T3 (da) 2011-12-05
US20130236420A1 (en) 2013-09-12
ES2662700T9 (es) 2018-08-27
CN102300570B (zh) 2015-01-14
ES2374117T3 (es) 2012-02-13
CA2703834C (en) 2014-05-20
AU2008323156B2 (en) 2012-05-31
ATE525070T1 (de) 2011-10-15
PT2219642E (pt) 2011-10-18
US20110182858A1 (en) 2011-07-28
JP2011503133A (ja) 2011-01-27
EP2392326B1 (en) 2018-01-24
EP2219642A1 (en) 2010-08-25
CA2703834A1 (en) 2009-05-22
KR101435242B1 (ko) 2014-08-29
PL2219642T3 (pl) 2012-02-29
AU2008323156A1 (en) 2009-05-22
ES2662700T3 (es) 2018-04-09
EP2392326A1 (en) 2011-12-07
EP2219642B1 (en) 2011-09-21
US9248115B2 (en) 2016-02-02
MX2010005107A (es) 2010-05-27
EP2392326B9 (en) 2018-09-05
JP5349486B2 (ja) 2013-11-20
HK1142270A1 (en) 2010-12-03

Similar Documents

Publication Publication Date Title
HK1142270A1 (en) Silibinin component for the treatment of hepatitis
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
GB0700436D0 (en) Impulse therapy for enhanced blood circulation in the body
IL186662A (en) Use of bis (thiohydrazide amide) to prepare a drug for the treatment of human cancer
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
PL2125004T3 (pl) Synergiczne zastosowanie terapeutyczne koncentratów czynników zespołu protrombiny z koncentratami FVIII
EP1789034A4 (en) COMPOUNDS HAVING A DIPHENYL STRUCTURE FOR THE TREATMENT OF IMMUNE DISEASES
WO2007135172A3 (en) Cladribine regimen for treating multiple sclerosis
HK1129315A1 (en) Method of treating hepatitis c patients
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
IL211810A0 (en) Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis
HK1119592A1 (en) Interferon lambda therapy for treatment of respiratory diseases
GB2427361B (en) Treatment device for the human body
EP1877420A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
ZA200806949B (en) Medicinal formulation for the treatment for hepatitis C
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
SI1714647T1 (sl) Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
GB0415181D0 (en) Compounds for use in the treatment of infection
TW200740455A (en) PEG-IFN alpha and ribavirin for HBV treatment
WO2008003514A3 (en) Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
GB0509911D0 (en) Medical treatment aid for use in treating children
MX2009011214A (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
ITMI20050108U1 (it) Apparecchiatura per il trattamento del corpo umano
TH0801000702A (th) อะคลิดิเนียมสำหรับใช้โดยการสูดในการบำบัดโรคทางเดินหายใจ